Lobbying on Prescription drugs

Novo Nordisk spent $350,000 lobbying in 2Q
Thursday August 28, 11:21 am ET
Drugmaker Novo Nordisk spent $350,000 lobbying government in second quarter


WASHINGTON (AP) -- Danish drugmaker Novo Nordisk AS spent $350,000 lobbying the U.S. government in the second quarter, according to a recent disclosure report.
The company lobbied on drug importation, patient safety protection, a bill to reduce health disparities, patent reform, diabetes patient care, and the Medicare Prescription Drug Price Negotiation Act, among other topics.

Novo Nordisk lobbied Congress, the Patent and Trademark Office, Department of Health and Human Services, Centers for Medicare and Medicaid Services, and the Office of Management and Budget.

Among those registered to lobby for Novo Nordisk in the April-June period was Lauren Semeniuk, who used to be legislative director for Rep. Cliff Stearns, R-Fla.

The company spent $330,000 lobbying on many of the same issues in the first quarter.